(Q35268615)

7 August 2017

title

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine (English)

1 reference

7 August 2017

1 reference

3

Allan Hildesheim

0 references

Sholom Wacholder

15

Sholom Wacholder

0 references

Ana Cecilia Rodríguez

2

Ana Cecilia Rodriguez

0 references

Mark Schiffman

6

Mark Schiffman

1 reference

7 August 2017

1

Aimée R Kreimer

1 reference

7 August 2017

4

Rolando Herrero

1 reference

7 August 2017

11

Douglas R Lowy

1 reference

7 August 2017

14

John Schussler

1 reference

7 August 2017

13

Mark E Sherman

1 reference

7 August 2017

Carolina Vargas-Porras

5

Carolina Porras

1 reference

Costa Rica HPV Vaccine Trial (CVT) Group

7 August 2017

16

CVT Vaccine Group

1 reference

7 August 2017

12

Wim Quint

1 reference

7 August 2017

8

Diane Solomon

1 reference

7 August 2017

Paula González

7

1 reference

7 August 2017

Silvia Jiménez

9

1 reference

7 August 2017

John T Schiller

10

1 reference

7 August 2017

language of work or name

English

0 references

publication date

9 September 2011

1 reference

Journal of the National Cancer Institute

7 August 2017

published in

1 reference

7 August 2017

volume

103

1 reference

7 August 2017

issue

19

1 reference

7 August 2017

page(s)

1444-1451

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

7 August 2017

copyright license

start time

4 October 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

National, state, and local area vaccination coverage among adolescents aged 13-17 years--United States, 2008.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3186781

26 September 2018

Identifiers

DOI

10.1093/JNCI/DJR319

1 reference

7 August 2017

1 reference

7 August 2017

1 reference